BioSpace News Archive

GE HealthCare, a leader in precision care innovation, will announce its third quarter 2023 financial results before the market opens on Tuesday, October 31, 2023.

Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing for bacterial infections, announced the appointments of Tim Skansi as Chief Financial Officer and Travis Davies as Vice President of Operations.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023.

GRI Bio, Inc. announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research Collaboration to advance its leading NKT regulation technology to treat inflammatory, fibrotic and autoimmune diseases.

ValGenesis successfully concluded its annual user conference on Thursday, September 28th, having presented an impressive series of product innovations for 2024 to customers, partners, and industry experts.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023.

SELLAS Life Sciences Group, Inc. announced that the topline clinical data from the final analysis of the Phase 1/2 clinical trial of galinpepimut-S in combination with pembrolizumab in Wilms’ tumor-1 -positive platinum-resistant ovarian cancer will be presented at an e-Poster session at the 2023 International Gynecologic Cancer Society Annual Global Meeting taking place November 5-7, 2023, in Seoul, South Korea.

BD, a leading global medical technology company, announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.

TeselaGen Biotechnology Inc., the software company providing an all-in-one platform for seamless, scalable biotech R&D, announces the acquisition of two cutting-edge patents that advance AI-driven optimization of biological phenotypes.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) today announced the launch of its TeloViewSMM to clinicians in the United States.